Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin Liang

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Pharmaceutics|April 23, 2022
Peptide-Based Vaccine against SARS-CoV-2: Peptide Antigen Discovery and Screening of Adjuvant SystemsAhmed O Shalash, Armira Azuar, Harrison Y R Madge, et al.
Nature Communications|June 16, 2023
Structure and antigenicity of divergent Henipavirus fusion glycoproteinsAriel Isaacs, Yu Shang Low, Kyle L Macauslane, et al.
Cell Reports|August 11, 2021
No evidence of human genome integration of SARS-CoV-2 found by long-read DNA sequencingNathan Smits, Jay Rasmussen, Gabriela O Bodea, et al.
Frontiers in Microbiology|March 1, 2021
An Optimized High-Throughput Immuno-Plaque Assay for SARS-CoV-2Alberto A Amarilla, Naphak Modhiran, Yin Xiang Setoh, et al.
Journal of Medical Virology|October 13, 2025
Vaccine-Induced and Hybrid Immunity Against SARS-CoV-2 Variants of Concern in Two Cohorts in Queensland, Australia (2021-2022)Rhys H Parry, Yingjun Shang, Julian D J Sng, et al.
Nature Communications|September 26, 2025
A single residue in the yellow fever virus envelope protein modulates virion architecture and antigenicitySumma Bibby, James Jung, Yu Shang Low, et al.
Vaccines|April 23, 2022
Dermal Delivery of a SARS-CoV-2 Subunit Vaccine Induces Immunogenicity against Variants of ConcernChristopher L D McMillan, Armira Azuar, Jovin J Y Choo, et al.
Science Advances|October 29, 2021
Complete protection by a single-dose skin patch-delivered SARS-CoV-2 spike vaccineChristopher L D McMillan, Jovin J Y Choo, Adi Idris, et al.
Ebiomedicine|October 21, 2023
Long-term safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18-55 years or ≥56 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trialKeith J Chappell, Francesca L Mordant, Alberto A Amarilla, et al.
The Journal of Infectious Diseases|November 24, 2025
Safety and immunogenicity of a SARS-CoV-2 spike, subunit vaccine stabilised in the prefusion conformation by second generation Molecular Clamp evaluated in adults aged 18-55 years: a randomised, double-blind, active comparator, Phase I trialKeith J Chappell, Francesca L Mordant, Alberto A Amarilla, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Pharmaceutics|April 23, 2022
Peptide-Based Vaccine against SARS-CoV-2: Peptide Antigen Discovery and Screening of Adjuvant SystemsAhmed O Shalash, Armira Azuar, Harrison Y R Madge, et al.
Nature Communications|June 16, 2023
Structure and antigenicity of divergent Henipavirus fusion glycoproteinsAriel Isaacs, Yu Shang Low, Kyle L Macauslane, et al.
Cell Reports|August 11, 2021
No evidence of human genome integration of SARS-CoV-2 found by long-read DNA sequencingNathan Smits, Jay Rasmussen, Gabriela O Bodea, et al.
Frontiers in Microbiology|March 1, 2021
An Optimized High-Throughput Immuno-Plaque Assay for SARS-CoV-2Alberto A Amarilla, Naphak Modhiran, Yin Xiang Setoh, et al.
Journal of Medical Virology|October 13, 2025
Vaccine-Induced and Hybrid Immunity Against SARS-CoV-2 Variants of Concern in Two Cohorts in Queensland, Australia (2021-2022)Rhys H Parry, Yingjun Shang, Julian D J Sng, et al.
Nature Communications|September 26, 2025
A single residue in the yellow fever virus envelope protein modulates virion architecture and antigenicitySumma Bibby, James Jung, Yu Shang Low, et al.
Vaccines|April 23, 2022
Dermal Delivery of a SARS-CoV-2 Subunit Vaccine Induces Immunogenicity against Variants of ConcernChristopher L D McMillan, Armira Azuar, Jovin J Y Choo, et al.
Science Advances|October 29, 2021
Complete protection by a single-dose skin patch-delivered SARS-CoV-2 spike vaccineChristopher L D McMillan, Jovin J Y Choo, Adi Idris, et al.
Ebiomedicine|October 21, 2023
Long-term safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18-55 years or ≥56 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trialKeith J Chappell, Francesca L Mordant, Alberto A Amarilla, et al.
The Journal of Infectious Diseases|November 24, 2025
Safety and immunogenicity of a SARS-CoV-2 spike, subunit vaccine stabilised in the prefusion conformation by second generation Molecular Clamp evaluated in adults aged 18-55 years: a randomised, double-blind, active comparator, Phase I trialKeith J Chappell, Francesca L Mordant, Alberto A Amarilla, et al.
Pageof 3